YTEN on NASDAQ

Yield10 Bioscience

Agricultural Science Company

Yield10 Bioscience (formerly Metabolix, Inc.) is a company developing new technologies to achieve improvements in crop yield to enhance global food security.3 It was founded by Anthony J Sinskey.1 Its shares trade on NASDAQ under the symbol YTEN.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1992Founded1

Compare with ESG Inc., Agroz Inc. or ORIENTAL RISE HOLDINGS Ltd, or pick any stock.

  • TickerYTEN on NASDAQ1
  • IndustryAgricultural Production-Crops1
  • HeadquartersCambridge1
  • Websitewww.yield10bio.com
  • Listed onNasdaq (MBLX), Nasdaq (YTEN)1
  • Incorporated inDE5
  • Business address19 Presidential Way, Suite 201, Woburn, Ma 018015
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation4
  • LEI5493008TC8RB9CSBE6964
  • StatusInactive4
  • LEI statusRetired4
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 29244864

Yield10 Bioscience (formerly Metabolix, Inc.) is a company developing new technologies to achieve improvements in crop yield to enhance global food security.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-24028.3%Operating margin7
-24091.7%Net margin7
-86.7%Revenue growth, 20237
-$10.1MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Selling, general and admin100¢$6.2M

Out of $60.0K in revenue.7 The company lost money this year.

Financial statements

Revenue891011127$60.0K in 2023−94% since 2017
0$250.0K$500.0K$750.0K$1.0M2017: $944.0K$944.0K20172018: $556.0K$556.0K2018−41%2019: $806.0K$806.0K2019+45%2020: $799.0K$799.0K2020−1%2021: $614.0K$614.0K2021−23%2022: $450.0K$450.0K2022−27%2023: $60.0K$60.0K2023−87%
Operating income891011127-$14.4M in 2023+55% since 2017
-$15.0M-$10.0M-$5.0M02017: -$9.3M-$9.3M20172018: -$9.3M-$9.3M2018+0%2019: -$8.6M-$8.6M2019−8%2020: -$9.6M-$9.6M2020+12%2021: -$11.7M-$11.7M2021+22%2022: -$13.5M-$13.5M2022+15%2023: -$14.4M-$14.4M2023+7%
Net income891011127-$14.5M in 2023+54% since 2017
-$15.0M-$10.0M-$5.0M02017: -$9.4M-$9.4M20172018: -$9.2M-$9.2M2018−2%2019: -$13.0M-$13.0M2019+41%2020: -$10.2M-$10.2M2020−21%2021: -$11.0M-$11.0M2021+8%2022: -$13.6M-$13.6M2022+23%2023: -$14.5M-$14.5M2023+7%
Fiscal year2017201820192020202120222023
Revenue$944.0K8$556.0K9$806.0K10$799.0K11$614.0K12$450.0K7$60.0K7
Cost of revenue
Selling, general and admin$5.6M8$5.1M9$4.6M10$5.0M11$6.1M12$6.2M7$6.2M7
Operating expenses$12.3M12$13.9M7$14.5M7
Operating income-$9.3M8-$9.3M9-$8.6M10-$9.6M11-$11.7M12-$13.5M7-$14.4M7
Income before tax-$11.0M12-$13.4M7-$14.5M7
Income tax$015$09-$254.0K10$56.0K11$36.0K12$156.0K7$07
Net income-$9.4M8-$9.2M9-$13.0M10-$10.2M11-$11.0M12-$13.6M7-$14.5M7
Earnings per share-$3.2915-$4.3011-$2.3312-$2.767-$1.827
Earnings per share (diluted)-$4.3011-$2.3312-$2.767-$1.827
Shares (weighted, basic)4.7M shares124.9M shares77.9M shares7
Shares (weighted, diluted)4.7M shares124.9M shares77.9M shares7

Compare Yield10 Bioscience with another company

Corporate structure

Yield10 Bioscience sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Yield10 Bioscience

  • Yield10 Bioscience Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Yield10 Bioscience reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.0M7 Dec 31, 2023$2.0M7 Dec 31, 2022+1.6%
Accumulated depreciation$1.5M7 Dec 31, 2023$1.2M7 Dec 31, 2022+20.9%
Property and equipment, net$548.0K7 Dec 31, 2023$775.0K7 Dec 31, 2022−29.3%
Operating-lease assets (leased space)$1.7M7 Dec 31, 2023$2.0M7 Dec 31, 2022−15.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.1M7 Dec 31, 2023$2.4M7 Dec 31, 2022−54.7%
Marketable securities, current$07 Dec 31, 2023$2.0M7 Dec 31, 2022−100.0%
Debt securities available for sale$2.0M7 Dec 31, 2022$10.7M12 Dec 31, 2021−81.3%
Long-term investments$07 Dec 31, 2023$07 Dec 31, 2022

The story

Founded by Anthony J Sinskey in 1992.1

Founded in 1992, with the help of a licensing agreement with Massachusetts Institute of Technology (MIT), Metabolix, Inc. is a bioscience company with headquarters in Cambridge, Massachusetts. Metabolix provides sustainable solutions to the plastic, chemical and energy industries. Oliver Peoples, Ph.D., and Anthony Sinskey, Ph.D., co-founded Metabolix after work at the (MIT) that identified the elementary methods and means for engineering polyhydroxyalkanoates production in plants and bacteria, thus making them biodegradable.

In early 2017, Metabolix became Yield10 Bioscience, its crop research program.

In 2024, Yield10 Biosciences filed for Chapter 11 bankruptcy protection, listing assets and liabilities between $1 million and $10 million.

From Wikipedia’s article on Yield10 Bioscience, shared under CC BY-SA 4.0.6

Leadership

Who has led Yield10 Bioscience, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (28)

Products and brands

Crop technologies

The centerpiece of the Metabolix's plant technology is polyhydroxybutyrate (PHB), the simplest member of the broad polyhydroxyalkanoate (PHA) family of biopolymers. They have worked with switchgrass, camelina, sugarcane, as well as tobacco.

In 2009, Metabolix completed a field trial producing PHA in a tobacco crop.

In 2012, Metabolix secured an ARPA-E grant to improve productivity of biofuel production in plants, specifically camelina.

In 2011, Metabolix was awarded a $6.0 million grant to produce PHB in switchgrass and to develop methods to thermally convert the PHB-containing switchgrass to crotonic acid and a higher density residual biomass fraction for production of biofuel.

Read the full text

In 2017, Yield10 participated in a Department of Energy program to help boost Camelina oilseed.

C3

C3 is the most common form of photosynthesis, existing in most crops suitable for human consumption, including wheat, canola, soybean and rice.

In 2019 Yield10 announced results from its 2018 field test, claiming that its C3003 gene trait showed an 11% increase in seed yield among canola crops, when compared to control plants. Similarly, C3003 met its objectives for soybean yield, and showed an increase in Camelina.

C4

C4 photosynthesis plants, like corn and sugar cane, possess a more complex system of metabolic pathways.

In 2018, Yield reported promising results for its C3004 gene trait in Camelina lines, following growth chamber studies.

CRISPR

Yield10 has also commenced development of CRISPR-enabled technology to impact crop yield. The company received a nonregulated status letter from the USDA-APHIS Biotechnology Regulatory Services (BRS) acknowledging that its camelina line has had a gene disrupted using CRISPR/Cas9 gene editing technology, resulting in the desired phenotype.

PHA-based Biomaterials

In 2019, Yield10 filed a U.S. Patent application for new technology enabling low-cost production of PHA-based biomaterials, knowing for their use in water treatment to remove nitrogen and phosphates, to maintain the viability and vigor of Camelina seed.

From Wikipedia’s article on Yield10 Bioscience, shared under CC BY-SA 4.0.6

Subsidiaries and ownership

Owners

From Wikidata.1

Former names

  • METABOLIX, INC.Aug 10, 2006 to Jan 6, 20175
  • METABOLIX INCApr 25, 2002 to Jul 14, 20065

Timeline

  1. Dec 6, 20248-K Bankruptcy or receivership; Exit or restructuring costs; Executive or director change49
  2. Nov 22, 20248-K Shareholder vote50
  3. Nov 12, 20248-K Entered a material agreement; Shareholder vote; Other events51
  4. Oct 31, 20248-K Executive or director change52
  5. Oct 3, 20248-K Entered a material agreement; Executive or director change; Other events53
  6. Sep 9, 20248-K Entered a material agreement; New debt or obligation54
  7. Jul 23, 20248-K Ended a material agreement55
  8. Jul 17, 20248-K Entered a material agreement56
  9. Jun 12, 20248-K Bylaws or fiscal year changed57
  10. Jun 10, 20248-K Executive or director change; Shareholder vote58
  11. May 15, 20248-K Listing notice or transfer; Other events59
  12. May 15, 20248-K Results of operations60
  13. Oct 28, 2016New chief executive Oliver P. Peoples becomes CEO16
  14. Jan 29, 2014New chief executive Joseph H. Shaulson becomes CEO17
  15. Mar 18, 2008New chief executive Richard P. Eno becomes CEO18
  16. Sep 17, 2007New chief executive Jay Kouba becomes CEO19
  17. Nov 10, 2006Went public Listed on NASDAQ1
  18. Nov 9, 2006New chief executive James J. Barber becomes CEO20
  19. 1992Founded Founded1

Calendar

When it reported results

  1. May 15, 2024Reported quarterly or annual results60
  2. Apr 1, 2024Reported quarterly or annual results61
  3. Nov 14, 2023Reported quarterly or annual results62
  4. Aug 14, 2023Reported quarterly or annual results63
  5. May 10, 2023Reported quarterly or annual results64
  6. Mar 14, 2023Reported quarterly or annual results65
  7. Nov 14, 2022Reported quarterly or annual results66
  8. Aug 10, 2022Reported quarterly or annual results67

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

183 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 49 major events, 79 insider forms, 6 large holders, 37 other. The latest 20:

  1. Dec 6, 20248-K EDGAR
  2. Nov 22, 20248-K EDGAR
  3. Nov 12, 20248-K EDGAR
  4. Oct 31, 20248-K EDGAR
  5. Oct 16, 2024DEFM14A EDGAR
  6. Oct 3, 20248-K EDGAR
  7. Oct 2, 2024PREM14A PRE 14A EDGAR
  8. Sep 9, 20248-K EDGAR
  9. Aug 20, 20244 EDGAR
  10. Aug 19, 20244 OWNERSHIP DOCUMENT EDGAR
  11. Aug 19, 20244 OWNERSHIP DOCUMENT EDGAR
  12. Aug 19, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Aug 14, 202410-Q EDGAR
  14. Jul 29, 2024424B3 EDGAR
  15. Jul 24, 2024EFFECT EDGAR
  16. Jul 23, 20248-K EDGAR
  17. Jul 22, 2024CORRESP EDGAR
  18. Jul 19, 202425-NSE EDGAR
  19. Jul 17, 20248-K EDGAR
  20. Jun 12, 20248-K EDGAR

The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

60 open-market trades by officers, directors and large owners since October 2021: 12 buys and 48 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 20, 2023SCHULER JACK W10% ownerSale36,000$0.20$7.2KForm 4
Dec 19, 2023SCHULER JACK W10% ownerSale36,000$0.21$7.6KForm 4
Dec 8, 2023SCHULER JACK W10% ownerSale35,000$0.24$8.4KForm 4
Oct 6, 2023SCHULER JACK W10% ownerSale37,931$0.30$11.4KForm 4
Oct 5, 2023SCHULER JACK W10% ownerSale10,670$0.30$3.2KForm 4
Oct 4, 2023SCHULER JACK W10% ownerSale41,399$0.31$12.8KForm 4
Aug 15, 2023SCHULER JACK W10% ownerBuy765,000$0.65$497.2KForm 4
May 5, 2023SCHULER JACK W10% ownerBuy335,570$2.98$1.0MForm 4
Dec 20, 2022SCHULER JACK W10% ownerSale608$1.78$1.1KForm 4
Dec 19, 2022SCHULER JACK W10% ownerSale5,100$1.76$9.0KForm 4
Dec 16, 2022SCHULER JACK W10% ownerSale7,000$1.82$12.7KForm 4
Dec 15, 2022SCHULER JACK W10% ownerSale6,324$1.88$11.9KForm 4
Dec 14, 2022SCHULER JACK W10% ownerSale18,192$1.89$34.4KForm 4
Dec 13, 2022SCHULER JACK W10% ownerSale7,000$1.75$12.2KForm 4
Dec 12, 2022SCHULER JACK W10% ownerSale4,292$1.80$7.7KForm 4
Dec 9, 2022SCHULER JACK W10% ownerSale10,152$1.88$19.1KForm 4
Dec 8, 2022SCHULER JACK W10% ownerSale5,300$1.91$10.1KForm 4
Dec 7, 2022SCHULER JACK W10% ownerSale3,504$1.91$6.7KForm 4
Dec 6, 2022SCHULER JACK W10% ownerSale7,000$1.96$13.7KForm 4
Dec 5, 2022SCHULER JACK W10% ownerSale7,000$2.06$14.4KForm 4

All 60 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$332.8K 2020–2020
Money received by yearMoney received by year, 2020–2020: $332.8K in all. PPP loans $332.8K.$0$100K$200K$300K$400K2020 · PPP loans: $332.8K2020
Figures by year
YearPPP loansTotal
2020$332.8K$332.8K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA71. Matched to this company by name and state.

  1. Apr 15, 2020$332.8K PPP loan (first draw) from Citizens Bank, National Association71To YIELD10 BIOSCIENCE, INC., Woburn MA; $334.6K forgiven Nov 5, 2020

SEC filer profile

How Yield10 Bioscience is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARYIELD10 BIOSCIENCE, INC.2
  • CIK0001121702
  • Employer ID (EIN)04-31582892
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)0100 Agricultural Production-Crops2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address19 Presidential Way, Suite 201, Woburn, MA 018012
  • Phone617-583-17002
  • Shares outstanding657,160 as of Aug 12, 202414
  • Public float$9.8M as of Jun 30, 20237
  • On EDGAR sinceApr 25, 20022
  • Filings1,200 in all: 4 (549), 8-K (205), 10-Q (54), SC 13G/A (40), 3 (38), CORRESP (32), SC 13G (27), UPLOAD (25)2
    All 46 form types

    DEF 14A (23), S-8 (21), S-1/A (19), 10-K (18), 4/A (18), EFFECT (17), 424B5 (11), S-1 (11), SC 13D/A (11), 424B3 (7), PRE 14A (7), 424B4 (6), ARS (6), S-3 (6), SC 13D (6), 5 (4), 8-K/A (4), CT ORDER (4), REGDEX (4), FWP (3), 10-Q/A (2), 8-A12B (2), D (2), PREM14A (2), S-1MEF (2), S-3/A (2), 25-NSE (1), 424B2 (1), 8-A12B/A (1), AW (1), CERTNAS (1), DEFA14A (1), DEFM14A (1), DEL AM (1), NT 10-Q (1), POS AM (1), REGDEX/A (1), RW (1)

  • Latest filingsAnnual report (10-K) Apr 1, 2024
    Quarterly report (10-Q) Aug 14, 2024
    Proxy statement (DEF 14A) Apr 29, 2024
    Latest 8-K (8-K) Dec 6, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71